Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27392 | 1.00 | — | — | |
| SCHEMBL359932 | 1.00 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL10435134 | 1.00 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL138183 | 0.95 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL22129635 | 0.95 | ALDH1A1 (0.39) | ALDH1A1 | |
| Bromide SCHEMBL30533687 | 0.95 | — | — | |
| Water SCHEMBL30770120 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL6167947 | 0.95 | — | — | |
| SCHEMBL499430 | 0.94 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL893278 | 0.91 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584574-B1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20220034865-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON, INC. | 2022-02-03 | — | — | US | disclosed |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | TENSHA THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200110069-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3212654-B1 | BROMODOMAIN INHIBITORS | TENSHA THERAPEUTICS INC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3254105-B1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10336717-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-10124009-B2 | Bromodomain inhibitors | TENSHA THERAPEUTICS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180193350-A1 | TREATMENT OF NUT MIDLINE CARCINOMA | TENSHA THERAPEUTICS INC (US) | 2018-07-12 | — | — | US | disclosed |
| EP-3314005-A1 | TREATMENT OF NUT MIDLINE CARCINOMA | Tensha Therapeutics, Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2438043-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2406240-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2324032-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2010141424-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | ALDH1A1 2484/4885 |
| US-10336717-B2 | Inhibitors of beta-secretase | BACE1, BACE2, PSEN1 | ALDH1A1 2962/4885 |
| US-10124009-B2 | Bromodomain inhibitors | BRDT, BRD4, BRPF3 | ALDH1A1 4621/4885 |
| US-20200110069-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | INSR, IAPP, GPR119 | ALDH1A1 1102/4885 |
| US-20220034865-A1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | INSR, IAPP, GPR119 | ALDH1A1 1102/4885 |
| US-20180193350-A1 | TREATMENT OF NUT MIDLINE CARCINOMA | BRDT, NUTF2, NASP | ALDH1A1 3265/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | ALDH1A1 2962/4885 |
| US-10925881-B2 | Treatment of conditions associated with hyperinsulinaemia | GPR119, IAPP, SLC5A2 | ALDH1A1 1486/4885 |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | ALDH1A1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.